GRI Bio Inc Dossier - Source-backed chat

GRI Bio Inc

GRINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.96Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $4.3M

Enterprise Value −$6.8M

Shares Outstanding 2.2M diluted

Next Earnings Date14 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

GRI Bio, Inc. is a high-risk, high-reward clinical-stage biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases. The company's lead asset, GRI-0621, recently achieved positive Phase 2a clinical data in Idiopathic Pulmonary Fibrosis (IPF) and secured FDA Orphan Drug Designation, validating its scientific platform. However, GRI Bio faces severe financial constraints, characterized by an ongoing going-concern warning and a cash balance of $11.05 million that is insufficient to complete the critical Phase 2b trial without substantial additional capital. Consequently, near-term performance is highly dependent on dilutive equity financing or securing a strategic partnership, justifying a Hold recommendation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$21.00

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.8015%

The bear case materializes if GRI Bio fails to raise sufficient capital to initiate the Phase 2b trial of GRI-0621, leading to clinical delays. Continued cash burn without strategic support could exacerbate going-concern doubts, potentially forcing the company to halt development or face delisting from the Nasdaq Capital Market if it cannot maintain compliance with minimum bid price or equity requirements.

Base CaseCentral scenario

$21.0060%

Matches the consensus mean

In the base case, GRI Bio continues to advance its clinical planning for GRI-0621 and IND-enabling activities for GRI-0803. The company will likely rely heavily on its amended $60 million At-The-Market (ATM) facility to fund operations, leading to ongoing shareholder dilution. While the scientific platform remains promising, the stock is expected to trade sideways or experience downward pressure due to the overhang of equity dilution and the lack of near-term commercial revenues.

Bull CaseUpside scenario

$32.0025%

The bull case is driven by the therapeutic potential of GRI-0621, which demonstrated positive safety, tolerability, and efficacy trends (such as FVC improvement and reduction of standard-of-care toxicities) in its Phase 2a trial. The FDA's Orphan Drug Designation provides seven years of market exclusivity and regulatory incentives. If GRI Bio secures a non-dilutive strategic partnership or a major licensing deal to fund the Phase 2b trial, the stock could experience significant upward revaluation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Positive Phase 2a clinical data for lead candidate GRI-0621 in IPF, demonstrating disease-modifying potential and reduction of standard-of-care side effects.
FDA Orphan Drug Designation granted to GRI-0621 in June 2026, offering potential tax credits, fee waivers, and seven years of market exclusivity upon approval.
Novel NKT cell modulation platform targeting early-stage inflammatory cascades, applicable to a broad range of fibrotic and autoimmune diseases.

Key Investment Risks

Severe capital deficit with a cash runway that is insufficient to complete the Phase 2b trial of GRI-0621 without substantial additional financing.
High risk of ongoing shareholder dilution due to heavy reliance on equity financing, outstanding warrants, and the At-The-Market (ATM) program.
Going concern warning issued by auditors, highlighting the company's financial fragility and dependence on external funding.

Thesis Invalidation Triggers

Failure to initiate the Phase 2b clinical trial of GRI-0621 due to lack of funding or regulatory delays.
Inability to maintain compliance with Nasdaq listing requirements, leading to delisting to over-the-counter markets.
Unfavorable safety or efficacy signals in upcoming clinical or preclinical readouts for GRI-0621 or GRI-0803.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.